Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy
Currently, survival of breast cancer patients with brain metastasis ranges from 2 to 16 months. In experimental brain metastasis studies, only 10% of lesions with the highest permeability exhibited cytotoxic responses to paclitaxel or doxorubicin. Therefore, radiation is the most frequently used tre...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/14/4/8306 |
id |
doaj-7e5d0440819448308577eebb4ecbac57 |
---|---|
record_format |
Article |
spelling |
doaj-7e5d0440819448308577eebb4ecbac572020-11-24T21:53:28ZengMDPI AGInternational Journal of Molecular Sciences1422-00672013-04-011448306832710.3390/ijms14048306Development of a Preclinical Therapeutic Model of Human Brain Metastasis with ChemoradiotherapyIgnasi ModolellAngels SierraCristina PicónVanessa HernándezAntonio Martínez-ArandaCurrently, survival of breast cancer patients with brain metastasis ranges from 2 to 16 months. In experimental brain metastasis studies, only 10% of lesions with the highest permeability exhibited cytotoxic responses to paclitaxel or doxorubicin. Therefore, radiation is the most frequently used treatment, and sensitizing agents, which synergize with radiation, can improve the efficacy of the therapy. In this study we used 435-Br1 cells containing the fluorescent protein (eGFP) gene and the photinus luciferase (PLuc) gene to develop a new brain metastatic cell model in mice through five in vivo/in vitro rounds. BR-eGFP-CMV/Luc-V5 brain metastatic cells induce parenchymal brain metastasis within 60.8 ± 13.8 days of intracarotid injection in all mice. We used this model to standardize a preclinical chemoradiotherapy protocol comprising three 5.5 Gy fractions delivered on consecutive days (overall dose of 16.5 Gy) which improved survival with regard to controls (60.29 ± 8.65 vs. 47.20 ± 11.14). Moreover, the combination of radiotherapy with temozolomide, 60 mg/Kg/day orally for five consecutive days doubled survival time of the mice 121.56 ± 52.53 days (Kaplan-Meier Curve, p < 0.001). This new preclinical chemoradiotherapy protocol proved useful for the study of radiation response/resistance in brain metastasis, either alone or in combination with new sensitizing agents.http://www.mdpi.com/1422-0067/14/4/8306brain metastasisbreast cancerexperimental modelsradiationtemozolomidetherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ignasi Modolell Angels Sierra Cristina Picón Vanessa Hernández Antonio Martínez-Aranda |
spellingShingle |
Ignasi Modolell Angels Sierra Cristina Picón Vanessa Hernández Antonio Martínez-Aranda Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy International Journal of Molecular Sciences brain metastasis breast cancer experimental models radiation temozolomide therapy |
author_facet |
Ignasi Modolell Angels Sierra Cristina Picón Vanessa Hernández Antonio Martínez-Aranda |
author_sort |
Ignasi Modolell |
title |
Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy |
title_short |
Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy |
title_full |
Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy |
title_fullStr |
Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy |
title_full_unstemmed |
Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy |
title_sort |
development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2013-04-01 |
description |
Currently, survival of breast cancer patients with brain metastasis ranges from 2 to 16 months. In experimental brain metastasis studies, only 10% of lesions with the highest permeability exhibited cytotoxic responses to paclitaxel or doxorubicin. Therefore, radiation is the most frequently used treatment, and sensitizing agents, which synergize with radiation, can improve the efficacy of the therapy. In this study we used 435-Br1 cells containing the fluorescent protein (eGFP) gene and the photinus luciferase (PLuc) gene to develop a new brain metastatic cell model in mice through five in vivo/in vitro rounds. BR-eGFP-CMV/Luc-V5 brain metastatic cells induce parenchymal brain metastasis within 60.8 ± 13.8 days of intracarotid injection in all mice. We used this model to standardize a preclinical chemoradiotherapy protocol comprising three 5.5 Gy fractions delivered on consecutive days (overall dose of 16.5 Gy) which improved survival with regard to controls (60.29 ± 8.65 vs. 47.20 ± 11.14). Moreover, the combination of radiotherapy with temozolomide, 60 mg/Kg/day orally for five consecutive days doubled survival time of the mice 121.56 ± 52.53 days (Kaplan-Meier Curve, p < 0.001). This new preclinical chemoradiotherapy protocol proved useful for the study of radiation response/resistance in brain metastasis, either alone or in combination with new sensitizing agents. |
topic |
brain metastasis breast cancer experimental models radiation temozolomide therapy |
url |
http://www.mdpi.com/1422-0067/14/4/8306 |
work_keys_str_mv |
AT ignasimodolell developmentofapreclinicaltherapeuticmodelofhumanbrainmetastasiswithchemoradiotherapy AT angelssierra developmentofapreclinicaltherapeuticmodelofhumanbrainmetastasiswithchemoradiotherapy AT cristinapicon developmentofapreclinicaltherapeuticmodelofhumanbrainmetastasiswithchemoradiotherapy AT vanessahernandez developmentofapreclinicaltherapeuticmodelofhumanbrainmetastasiswithchemoradiotherapy AT antoniomartinezaranda developmentofapreclinicaltherapeuticmodelofhumanbrainmetastasiswithchemoradiotherapy |
_version_ |
1725872053498675200 |